Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis

2020 ◽  
Vol 34 (7) ◽  
pp. 851-865 ◽  
Author(s):  
Xiaoxia Wu ◽  
Lei Yang ◽  
Ying Wang ◽  
Chunfeng Wang ◽  
Rong Hu ◽  
...  

Objectives: Combined aerobic and resistance exercise (CARE) is beneficial for improving renal function. To confirm this, we conducted a meta-analysis to evaluate the effects of CARE on renal function in adult patients with chronic kidney disease (CKD). Date sources: The last date of search was 22 February 2020. We searched Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Allied and Complementary Medicine (AMED), CINAHL, Web of Science, SPORTDiscus, and three Chinese databases (China National Knowledge Infrastructure (CNKI), Wangfang, Journal Integration Platform (VIP)) for articles of randomized and quasi-randomized controlled trials. Methods: We used the Cochrane tool and the JBI Critical Appraisal checklist to assess randomized controlled trials and quasi-randomized controlled trials, respectively. Result: A total of 12 studies and 745 patients were included. Compared with usual care or no exercise, CARE resulted in a significant improvement in the estimated glomerular filtration rate (between-group analysis: mean difference (MD) =5.01, 95% confidence interval (CI): 2.37 to 7.65; within-group analysis: MD = 3.01, 95% CI: 0.86 to 5.16). The serum creatinine levels also showed a significant improvement after CARE (between-group analysis: MD = −8.57, 95% CI: −13.71 to −3.43; within-group analysis: MD = −6.33, 95% CI: −10.23 to −2.44). Patients who performed CARE also demonstrated a decline in the blood pressure in the within-group analysis (systolic blood pressure: MD = −5.24, 95% CI: −7.93 to −2.54; diastolic blood pressure: MD = −3.63, 95% CI: −5.35 to −1.91). However, there were no significant differences in proteinuria, lipid levels, physical composition, and quality of life. Conclusion: The study results support the concept that CARE intervention improves renal function. It provides strong evidence for guiding clinical decisions and implementing renal rehabilitation exercises.

PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0233869
Author(s):  
Stephanie Thompson ◽  
Natasha Wiebe ◽  
Raj S. Padwal ◽  
Gabor Gyenes ◽  
Samuel A. E. Headley ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0211032 ◽  
Author(s):  
Stephanie Thompson ◽  
Natasha Wiebe ◽  
Raj S. Padwal ◽  
Gabor Gyenes ◽  
Samuel A. E. Headley ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Sherida Edding ◽  
Brian Michael Cabral ◽  
Monica Therese Cating-Cabral

Abstract Background and Aims Hyperuricemia is associated with rapid deterioration of renal function in patients with chronic kidney disease (CKD). The two most common urate-lowering drugs available in the market are allopurinol and febuxostat. Randomized controlled trials (RTCs) have shown that the individual drugs have potential to slow down progression of renal function in patients with chronic kidney disease (CKD) and hyperuricemia. However, it is unclear which drug is more effective because of insufficient direct comparison between the two. Hence our study aims to perform a meta-analysis of RCTs to assess the renoprotective and urate-lowering effects between the two drugs in patients with CKD and hyperuricemia. Method A comprehensive literature search of randomized controlled trials using PubMed was performed with the following search terms: febuxostat, allopurinol, chronic kidney disease, renoprotection. Four prospective RCTs were selected and analyzed using Cochrane Revman v5.3. Outcomes assessed were change in serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria and serum uric acid levels from baseline to 3 months post-initiation of therapy. Results Four relevant trials comprising of 486 patients were selected - 247 patients treated with febuxostat and 239 patients with allopurinol. No significant differences were found in the changes in serum creatinine (mean difference -0.04; CI -0.15, 0.07; P = 0.51) and eGFR (mean difference 1.57; CI -0.83, 3.97; P = 0.20) from baseline to 3 months between the febuxostat and allopurinol group. Decrease in proteinuria was significantly observed more in the febuxostat group (mean difference -50.13; CI -90.54; -9.71, P = 0.02). Similarly, serum uric acid levels were significantly more reduced in the febuxostat group (mean difference -1.11; CI -1.53, -0.68, P < 0.00001). Conclusion Our study showed that febuxostat is non-inferior in terms of delaying renal function decline (as measured by eGFR) but it offers a better anti-proteinuric as well as a urate-lowering effect. However, more studies are needed to assess the efficacy of febuxostat across the spectrum of chronic kidney disease, including those requiring hemodialysis.


2018 ◽  
Vol 7 (3) ◽  
pp. 106-114 ◽  
Author(s):  
Charat Thongprayoon ◽  
Spencer T. Hatch ◽  
Wisit Kaewput ◽  
Konika Sharma ◽  
Patompong Ungprasert ◽  
...  

Nephron ◽  
2018 ◽  
Vol 139 (3) ◽  
pp. 197-210 ◽  
Author(s):  
Primploy Greeviroj ◽  
Thidarat Kitrungphaiboon ◽  
Pisut Katavetin ◽  
Kearkiat Praditpornsilpa ◽  
Somchai Eiam-Ong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document